The number of U.S. states with adult obesity rates at or above 35% has declined for the first time in over a decade, dropping from 23 states in 2023 to 19 in 2024, according to a new report. This improvement is potentially driven by the wider adoption of GLP-1 weight-loss drugs such as Wegovy and Zepbound, alongside increased nutrition assistance programs, some of which are now being phased out. While this signals a potential shift in the adult health landscape, childhood and teen obesity rates have simultaneously risen, and the national adult obesity rate remains high at 4 in 10, indicating a complex and evolving market impact for pharmaceutical companies, healthcare providers, and related sectors.
The number of U.S. states with adult obesity rates at or above 35% declined from 23 in 2023 to 19 in 2024, marking the first such reduction in over a decade, according to a Trust for America’s Health report. While 20 states saw declines, the national adult obesity rate remains high at 4 in 10, indicating persistent public health challenges. This improvement is partially linked to the increased adoption of GLP-1 weight-loss drugs such as Wegovy and Zepbound, suggesting continued strong demand for pharmaceutical innovations in obesity management. However, child and teen obesity rates concurrently rose to over 21% from 19.7%, signaling an emerging long-term healthcare market. The report also notes that increased nutrition assistance during the pandemic may have contributed to adult improvements, but some of these programs are now ending, and SNAP eligibility is tightening. This policy shift could counteract future progress in adult obesity and further strain pediatric health outcomes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment
